AbstractPurpose of review
This article reviews multiple secondary and primary prevention trials that have expanded the indications for implantable cardioverter-defibrillators (ICDs).Recent findings
Most studies performed over the last several years have concentrated on the role of ICDs in high-risk patients for the primary prevention of sudden death. Several recent trials that have been completed but not published are also reviewed.Summary
Data from recently completed trials and evolving ICD technology, such as ICDs with cardiac resynchronization capabilities, will alter indications for ICDs in the near future.